(Q48255430)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

The importance of FLT3 mutational analysis in acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Mrinal M Patnaik

series ordinal

1

1 reference

http://europepmc.org/abstract/MED/29164965

10 February 2018

publication date

22 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

2273-2286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

3 April 2020

copyright license

start time

22 November 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Genomic Classification and Prognosis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Rates of complete diagnostic testing for patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Precision medicine in acute myeloid leukemia: Hope, hype or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Leukemogenic potency of the novel FLT3-N676K mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Acute myeloid leukemia: focus on novel therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

How I treat FLT3-mutated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Inhibition of FLT3 in AML: a focus on sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Minimal residual disease in acute myeloid leukemia--current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1399312

10.1080/10428194.2017.1399312

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29164965%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference